title: Efficacy of propafenone for maintaining sinus rhythm in patients with recent onset or persistent atrial fibrillation after conversion: a randomized, placebo-controlled study.
abstract: OBJECTIVE
  The aim of this study was to investigate the efficacy and safety of propafenone in the prevention of atrial fibrillation (AF) relapse after restoration of sinus rhythm.
  
  
  METHODS
  This study consisted of 110 consecutive patients with recent onset and persistent AF. After restoration of sinus rhythm, patients were randomized to propafenone (n: 58, age: 60 +/- 12 years) or placebo (n: 52, age: 62 +/- 10 years).There were 11 withdrawals (7 in the propafenone and 4 in the placebo group) during follow-up. Follow-up evalutations were conducted at the first, 3rd and then at an interval of three months during 15 months. The clinical characteristics in both groups were comparable. The AF relapse was analysed by the Kaplan-Meier method.
  
  
  RESULTS
  At 15-month follow-up, AF relapsed in 20 (39%) and 31 (65%) patients in the propafenone and placebo groups, respectively (p = 0.015). In subgroup analysis, AF recurrence was significantly lower in the propafenone group than in the placebo group only in the recent onset AF patients with spontaneous conversion (21% vs. 61%, p = 0.01). However, the AF relapse rates were similar in patients with persistent AF and with recent AF who converted to sinus rhythm pharmacologically or electrically in the propafenone and placebo groups. Four patients on propafenone and one on placebo had adverse effects necessitating discontinuation of the drug (p = 0.36).
  
  
  CONCLUSIONS
  At 15 months, propafenone seems to be superior to placebo for maintaining sinus rhythm in patients with recent onset or peristent AF. This superiority originates mainly from patients with recent onset AF in whom sinus rhythm occurred spontaneously. Its adverse effects are similar to placebo.
authors.affiliation: Sevket Demirel Heart Center, Suleyman Demirel University, Isparta, Turkey. adogan35@hotmail.com
authors.forename: Abdullah
authors.initials: A
authors.lastname: Dogan
authors.forename: Oktay
authors.initials: O
authors.lastname: Ergene
authors.forename: Cem
authors.initials: C
authors.lastname: Nazli
authors.forename: Ozan
authors.initials: O
authors.lastname: Kinay
authors.forename: Ahmet
authors.initials: A
authors.lastname: Altinbas
authors.forename: Yesim
authors.initials: Y
authors.lastname: Ucarci
authors.forename: Ulku
authors.initials: U
authors.lastname: Ergene
authors.forename: Mehmet
authors.initials: M
authors.lastname: Ozaydin
authors.forename: Omer
authors.initials: O
authors.lastname: Gedikli
mesh_terms: D000889:Anti-Arrhythmia Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D001146:Arrhythmia, Sinus / Q000628:therapy; D001281:Atrial Fibrillation / Q000473:pathology / Q000517:prevention & control* / Q000628:therapy; D002908:Chronic Disease; D004554:Electric Countershock; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D010919:Placebos; D011405:Propafenone / Q000008:administration & dosage* / Q000627:therapeutic use; D055502:Secondary Prevention; D013997:Time Factors
chemical_list: D000889:Anti-Arrhythmia Agents; D010919:Placebos; D011405:Propafenone